Management
CEO: Tim Blair
tblair@nmddo.com
954 483 4525

CTO: Troy Long, MD
tlong13md@gmail.com
612 309 8406

VP R&D: Brett Naglreiter
bnaglreiter@nmddo.com

Controller: Deb Lundgren
dlundgren@nmddo.com

Strategic Partners
Legal – Dan White (FL)
Engineering – Naglreiter LLC (FL)
Manufacturing – Naglreiter LLC (FL)
IP Strategy - Dunlap Codding P.C.
Laboratory – NAMSA
Regulatory – Naglreiter LLC / NAMSA
Quality – Naglreiter (FL)
Reimbursement - JD Lymon (MN)

Current Investors
NAMSA
Naglreiter
Cleveland Clinic (GCIC)
OSF Healthcare Ventures
Cultivation Capital
Physician/Strategic Investors

Financing Sought (Strategic A)
Seeking $5M - $7M for an optimal exit or strong Commercial B Round. Secured $5M in Physician Funding and Strategic Investors to date.

Highlights
*Novel
*Medical Device
*Disruptive Technologies
*Minimally invasive
*Disposable
***510(k) approval Dec 21st, 2018**
*EU, MEX, BRA, CAN in 2020
*Strong KOL relationships, investments and feedback supports adoption
*Strong safety and efficacy profile in bench, preclinical, and FIH models
*Improving Health outcomes
*Improving Health economics
*Fits Office Based models (OBLs)
*Intuitive design fit today's workflows
*Addresses the non-surgical / non-thombolytic candidate
*$150M - $200M product lines

ICHOR Vascular Inc. has 510(k) market clearance for its percutaneous Embolectomy / Thrombectomy systems to treat a wide range of arterial and venous occlusions. Acute clot, thrombosed bypass grafts, occluded stents, organized thrombus, embolic events, and post atherectomy tibial occlusions have been successfully performed using ICHOR's Panacea technology. ICHOR's Aceso product is currently in development to treat venous thrombus.

PAD Market: 14+ million people worldwide suffer from Peripheral Arterial Disease (PAD). The most severe form of PAD is Acute Limb Ischemia (ALI) or Critical Limb Ischemia (CLI). Those with PAD are at increased risk for heart disease, aortic aneurysms, stroke and is commonly associated with diabetes or hypertension.

Panacea 7F Arterial Market: More than 200,000 Americans available to be treated with an ICHOR Panacea device.

- ~70,000 limbs diagnosed and treated as ALI (M Yost).
- >50,000 fem pop bypass failures (rarely reported as an ischemic event).
- >50,000 estimated pre CLI (organized thrombus).
- Thousands of occluded SFA stents treated as thrombectomy procedures.
- Incidence of clinically significant emboli from peripheral interventions reported between 2%-5% but significantly under-reported.
- PAD (In the US & EU) is responsible for ~240,000 amputations / year.
- ~25% of these patients die within 30 days & 50% within 1 year of amputation.
- Outcomes are essentially **unchanged in the last 30 years.**
- **Tools to treat lower limb disease are essentially borrowed, old, and unchanged**

Aceso 12F Venous Market: More than 400,000 Americans treated for deep vein thrombosis (DVT) of the lower limbs annually which can be treated with an ICHOR Aceso device. DVT of the lower limbs is equally growing like PAD and a common origination for Pulmonary Embolism (PE). ICHOR's ability to manage flow with proximal and distal protective elements will give physician's better options in lower limb clot management.

ICHOR Vascular Solution: Our 510(k) cleared **ICHOR system** will penetrate the peripheral arterial / venous market by replicating what works well in a surgical embolectomy but in a 7F or 12F percutaneous system. ICHOR will treat organized thrombus, acute occlusions, and venous thombus with superiority while driving an economic benefit that will further drive hospital adoption.

ICHOR Value Proposition: a "1 size fits all" Percutaneous Reperfusion System:

- Non-drug therapy = fewer complications, reduced ICU stay
- Non-surgical therapy = fewer complications, reduced ICU stay
- Avoids blood loss associated with aspiration and surgery
- No general anesthesia
- Avoids distal embolization
- Intuitive for any endovascular physician to use
- Addresses the Health Economics

Use of Series A Proceeds:

- Begin the venous development program
- Establish a commercial model that reduces Strategic risk and the foundation for sales expansion
- Collect real world data that appeals to adoption, podium worthy, and supports CE Mark
- Sales and Clinical enablement model / structure to get ICHOR to 400 procedures
- Complete QMS for FDA and EU audits (ISO certified)
- Obtain OUS registrations